UNSPSC 51172167: Dexsecoverine hydrochloride

This classification denotes the hydrochloride form of an antispasmotic agent and antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3O6AUX3I0J. European Medicines Agency schedules Dexsecoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07047MIG. Dexsecoverine generally arises in the molecular formula C22H35NO2.

UNSPSC 51172167 Dexsecoverine hydrochloride is a Commodity code that in practice frames drug-testing procurement for criminal justice and offender supervision. State and local governments buy specimen collection services, laboratory analysis (immunoassay screening with confirmatory testing by LC/MS/MS or GC/MS), result reporting, and alternative testing modalities including oral fluid and hair analysis under this code. Issuing bodies are primarily county criminal justice departments and community supervision agencies managing probation and pretrial caseloads. The work requires lab certification from SAMHSA, the Texas Department of Public Safety, or CAP, and vendors must staff collection sites during extended business hours plus weekend availability. Pricing models are per-test, with separate line items for screening-only, confirmation-after-screening, and screening-with-automatic-confirmation workflows.

Collin County Community Supervision and Corrections Department posted RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on September 25, 2026, with proposals due July 23, 2026 at 2:00 p.m. The scope encompasses staffing two collection sites in Plano and McKinney with annual testing demand of approximately 25,031 tests, comprising 5,452 five-panel screens, 18,006 six-panel screens, and ancillary testing. The estimated contract value is $600,000 over two years commencing September 1, 2026, with three optional one-year renewal periods. The county reserves the right to award in whole or in part to multiple vendors. Evaluation scores vendor understanding, firm qualifications, client references, and cost; optional demonstrations and interviews add up to 30 additional points. Price redetermination is limited to annual anniversaries and capped at 3.0 percent increases based on medical Consumer Price Index movement.